SIRT1 and neoplasm: Among the sirtuins, SIRT1, SIRT3, SIRT4, and SIRT6 have been identified as significant targets for anti-tumor treatments [26]; SIRT4 has been proposed as a tumor-suppressor protein, reducing glutamine entry into mitochondria in response to DNA damage [27,28].